Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Molecular Test Helps Personalize Chemotherapy for Advanced Prostate Cancer

By LabMedica International staff writers
Posted on 01 Sep 2025

Prostate cancer is the second most common cause of cancer death in men in the UK, with 55,100 new cases and 12,000 deaths expected annually. More...

Around 10,000 men in the UK are diagnosed with advanced prostate cancer each year, with most deaths occurring in patients diagnosed with advanced or metastatic disease. While treatment intensification with docetaxel alongside androgen deprivation therapy (ADT) can improve survival, response rates vary, and clinicians currently lack tools to identify who will benefit most. Now, a novel molecular test can help personalize the treatment of advanced prostate cancer and avoid unnecessary side effects of chemotherapy.

Researchers at University College London (UCL, London, UK) evaluated Veracyte’s (South San Francisco, CA, USA) Decipher Prostate Genomic Classifier test, a gene expression assay performed on routinely collected prostate tissue. The test, already widely used in the US to identify localized cancers likely to spread, is the first molecular tool with randomized trial evidence showing it can guide treatment choices for metastatic disease. The test works by profiling tumor gene expression to classify patients based on predicted chemotherapy sensitivity.

The study drew on data from 1,523 patients recruited to the STAMPEDE phase III trials who had advanced prostate cancer and began treatment with ADT. Participants received additional therapies, including abiraterone or docetaxel, and were followed for a median of 14 years. Among the 832 patients with metastatic prostate cancer, researchers linked molecular test results with long-term clinical outcomes, allowing them to assess the ability of the test to predict who benefited from docetaxel chemotherapy.

The results, published in Cell, show that among the 832 patients with metastatic prostate cancer, those with high Decipher scores had a 36% reduction in risk of death after docetaxel treatment, compared to less than 4% for those with low scores. The test consistently outperformed traditional clinical tools in identifying patients most likely to benefit. This provides the first strong evidence that a routinely available molecular test can influence chemotherapy decisions in advanced prostate cancer.

The findings highlight how gene expression tests could help avoid exposing patients unlikely to benefit to toxic side effects, while guiding others toward chemotherapy for longer survival. Additional analyses identified new molecular classifiers, including a signature linked to inactivity of the tumor suppressor gene PTEN, which predicts poorer hormone therapy response but greater chemotherapy benefit. Researchers believe these discoveries pave the way for reclassifying prostate cancer into molecular subtypes for more tailored treatments.

“The ability to personalize chemotherapy decisions based on the Decipher Prostate test will greatly enhance patient care and outcomes,” said Professor Gert Attard, lead researcher at UCL Cancer Institute and UCLH. “By identifying which patients are most likely to have a survival benefit from chemotherapy, we can avoid unnecessary side effects and develop alternative treatments for people with metastatic prostate cancer who are unlikely to benefit."

Related Links:
UCL
Veracyte


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.